Impact of Real-Time Continuous Glucose Monitoring Use on Glucose Variability and Endothelial Function in Adolescents with Type 1 Diabetes: New Technology—New Possibility to Decrease Cardiovascular Risk?

Table 3

Glucose variability depending on the initial HbA1c level.

		HbA1c before the study
		<7.5%	≥7.5%
HbA1c; (%)	Before the study; After the study	7.25 ± 0.19; 6.73 ± 0.47; 0.006	9.88 ± 1.22; 9.33 ± 1.62; 0.003
Mean glucose; (mg/dL)	1st week; Last week	127.75 ± 9.84; 126.75 ± 23.26; 0.8	178.28 ± 29.90; 149.31 ± 8.12; <0.001
Mean glucose SD (mg/dL)	1st week; Last week	46.75 ± 6.94; 44.75 ± 3.49; 0.286	64.88 ± 13.57; 55.75 ± 14.95; 0.003
AUC > 140 mg/dL	1st week; Last week	14.75 ± 6.94; 13.00 ± 3.52; 0.157	50.46 ± 24.33; 28.29 ± 17.65; <0.001
AUC < 70 mg/dL	1st week; Last week	0.98 ± 0.46; 0.68 ± 0.28; 0.203	0.49 ± 0.61; 0.58 ± 0.62; 0.957
Max glucose; (mg/dL)	1st week; Last week	279.75 ± 25.93; 291.50 ± 14.92; 0.14	375.26 ± 70.36; 339.13 ± 71.90; <0.001
Min glucose (mg/dL)	1st week; Last week	42.75 ± 1.75; 48 ± 5.45; 0.045	52.25 ± 13.17; 47.37 ± 6.65; 0.005
FMD (%)	Before the study; After the study	16.25 ± 4.32; 27.81 ± 6.49; 0.002	9.57 ± 6.44; 13.89 ± 6.43; <0.001

Results of RT-CGM are presented as mean ± SD.
: significant difference between two subgroups, considering the same time sensor usage (first or last week).